Neurology Central

Apomorphine yields positive results from TOLEDO study for Parkinson’s disease

Researchers from Britannia Pharmaceuticals Ltd (Reading, UK) have demonstrated that treatment of Parkinson’s disease (PD) patients with apomorphine, known by the tradenames APO-go® and MOVAPO®, can provide relief of persistent motor fluctuations. The improvements in PD symptoms allowed patients to significantly reduce the dose and number of administrations of their other PD medications.

Although current medications treat the symptoms of PD, some patients’ symptoms cannot be controlled by oral medication alone.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.